top of page

Taking a deep dive into last week's T-cell engager data with the CEO of Janux Therapeutics

David Campbell explains how Janux has used masking technology to improve the profile T-cell engagers in solid tumors, and goes over the company's recent PSMA and EGFR data.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page